TWM
CNTA

Tanager Wealth Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Tanager Wealth Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-598,044
Closed -$14.5M – 138
2025
Q3 		$14.5M Hold
598,044
– – 1.52% 21
2025
Q2 		$7.86M Sell
598,044
-98,052
-14% -$1.24M 0.93% 24
2025
Q1 		$10M Hold
696,096
– – 1.3% 19
2024
Q4 		$11.7M Hold
696,096
– – 1.51% 18
2024
Q3 		$11.1M Hold
696,096
– – 1.5% 19
2024
Q2 		$6.29M Hold
696,096
– – 0.94% 25
2024
Q1 		$7.87M Hold
696,096
– – 1.27% 21
2023
Q4 		$5.54M Hold
696,096
– – 1.01% 23
2023
Q3 		$4.5M Hold
696,096
– – 0.93% 21
2023
Q2 		$4.31M Sell
696,096
-40,963
-6% -$194K 0.93% 23
2023
Q1 		$2.84M Sell
737,059
-1,141,324
-61% -$4.18M 0.67% 27
2022
Q4 		$5.82M Buy
+1,878,383
New +$6.96M 1.57% 21

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Tanager Wealth Management's CNTA Position: Q4 2025 in Review

Tanager Wealth Management sold out of Centessa Pharmaceuticals (CNTA) in Q4 2025, closing a stake of 598,044 shares — an estimated $14.5M sold.

Tanager Wealth Management first reported a position in CNTA in Q4 2022 and held it in 12 quarters. The position peaked at $14.5M in Q3 2025. 146 funds tracked by Wall St. Rank hold CNTA as of Q4 2025.

  • Tanager Wealth Management reported no remaining Centessa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tanager Wealth Management sold 598,044 Centessa Pharmaceuticals shares in Q4 2025, an estimated $14.5M.
  • Tanager Wealth Management first reported a position in Centessa Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • Tanager Wealth Management's Centessa Pharmaceuticals position peaked at $14.5M in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2025.

Based on Tanager Wealth Management's 13F filing for Q4 2025, filed 26 Jan 2026.